Floatz logo

dr-0202

Gastroesophageal-junction Cancer

Dren BioPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

112 Active assets in the Gastroesophageal-junction Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

dr-0202 is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
urothelial carcinomaDormant
C
Indicative ·
39 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →